Bamco Inc. NY Boosts Stake in ARS Pharmaceuticals

Institutional investor increases ownership in biotech firm by over 3,000%

Mar. 16, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Bamco Inc. NY, an institutional investor, significantly increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 3,071.3% in the 3rd quarter, according to a recent SEC filing. The firm now owns 1,268,532 shares of the company's stock, making it a major shareholder with about 1.28% ownership.

Why it matters

This large increase in ownership by a prominent institutional investor like Bamco suggests growing confidence in ARS Pharmaceuticals and its pipeline of treatments for severe allergic reactions. It also highlights the biotech firm's potential for future growth and development.

The details

According to the filing, Bamco Inc. NY acquired an additional 1,228,532 shares of ARS Pharmaceuticals during the 3rd quarter, bringing its total stake to 1,268,532 shares. This represents a 3,071.3% increase in the firm's position. Other major investors in ARS Pharmaceuticals include Rubric Capital Management LP, Vanguard Group Inc., Aberdeen Group plc, and Franklin Resources Inc.

  • Bamco Inc. NY increased its stake in ARS Pharmaceuticals during the 3rd quarter of 2026.

The players

Bamco Inc. NY

An institutional investment firm that has significantly increased its ownership in ARS Pharmaceuticals.

ARS Pharmaceuticals, Inc.

A biopharmaceutical company developing treatments for severe allergic reactions, including its lead product candidate neffy, a needle-free and low-dose intranasal epinephrine nasal spray.

Got photos? Submit your photos here. ›

The takeaway

This large increase in ownership by a prominent institutional investor like Bamco suggests growing confidence in ARS Pharmaceuticals and its potential to develop innovative treatments for severe allergic reactions, a significant unmet medical need.